HIV Prevention Treatment Launch in France Could Transform AIDS Fight

France is poised for a significant shift in HIV prevention, as the introduction of a new prophylactic treatment could transform efforts to curb the spread of AIDS and reshape national public health strategies.

A Major Step Forward in HIV Prevention

A fresh chapter in the fight against HIV/AIDS is beginning in France, where authorities have officially authorized a new long-acting injectable preventive treatment, cabotegravir. After months of anticipation from medical experts and advocacy groups, the French government published a decree on February 26, 2026, enabling physicians to prescribe this therapy. The association Aides, which has been at the forefront of HIV activism, described the move as a “major breakthrough” for those at risk.

A New Alternative to Oral PrEP

Until now, individuals seeking protection from HIV infection had access only to oral pre-exposure prophylaxis (PrEP), which demands a disciplined routine of daily pill-taking. Adherence has posed challenges for many, leading some patients to interrupt or discontinue treatment altogether. With cabotegravir — sold under the name Apretude by ViiV Healthcare, a subsidiary of GSK — that burden may ease considerably. The injection, administered once every two months, promises greater convenience and could potentially expand the reach of preventive care.

Cautious Optimism and Ongoing Challenges

The arrival of this innovation has sparked optimism among public health officials and organizations like UNAIDS, which see cabotegravir as a possible game-changer in curbing new infections. Although the French health authority (HAS) endorsed its medical benefit as only “moderate” back in summer 2024, expectations remain high for its impact.

However, several factors explain why broad access is not yet guaranteed:

• The medication is not recommended for women who might become pregnant due to potential fetal risks.
• A prerequisite viral load test must be performed before prescribing cabotegravir — and this test isn’t fully reimbursed by the national health system.
• The high price per dose (exceeding €1,000) means that cost-sharing or insurance coverage can affect patients’ out-of-pocket expenses.

The Road Ahead: Equity and Expansion?

While negotiations between French health authorities and ViiV Healthcare have resulted in a confidential reimbursement agreement through national insurance, only those unable to use or tolerate oral PrEP will initially benefit from this therapy. As France moves into this new era of prevention, experts and activists alike stress that further adjustments are needed to ensure fair access — especially for vulnerable groups — so that cabotegravir’s promise does not remain out of reach for those who need it most.